Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9H2X6
UPID:
HIPK2_HUMAN
Alternative names:
-
Alternative UPACC:
Q9H2X6; Q75MR7; Q8WWI4; Q9H2Y1
Background:
Homeodomain-interacting protein kinase 2 (HIPK2) is a serine/threonine-protein kinase with pivotal roles in transcription regulation, cellular apoptosis, and cell cycle control. It functions as a corepressor of transcription factors like SMAD1 and POU4F1/Brn3a, and phosphorylates a wide array of substrates including p53/TP53, promoting apoptosis and inhibiting cell growth. HIPK2 is also involved in hypoxia response, angiogenesis, and erythroid differentiation, highlighting its multifaceted role in cellular processes.
Therapeutic significance:
Understanding the role of Homeodomain-interacting protein kinase 2 could open doors to potential therapeutic strategies.